Category
Compounding Pharmacy
3 articles
TGA Reform Priorities for 2027: Accelerating Access to Medicines for Australians
Australia's Therapeutic Goods Administration faces mounting pressure to modernise its approval pathways, expand biosimilar uptake, close the digital therapeutics regulatory gap, and strengthen post-market surveillance. A policy analysis of the reform agenda for 2027.
Compounding Pharmacy Regulation in Australia: The TGA, GLP-1 Shortages, and the Policy Tension
How TGA Section 19A, compounded semaglutide and tirzepatide during national shortages, the BPC-157 Schedule 4 reclassification, and Pharmacy Board notifications have turned compounding into a national policy issue balancing patient access against sterile-injectable safety.
TGA Regulation of Peptides in Australia: What Patients and Clinicians Need to Know
Australia's Therapeutic Goods Administration classifies peptides under a complex scheduling framework. This guide explains TGA peptide schedules, the March 2025 BPC-157 rescheduling, compounding pharmacy access, and what 'research use' means legally.